Cover Image
市場調查報告書

鹽野義製藥:產品平台分析

Shionogi & Co Ltd - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 251722
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
Back to Top
鹽野義製藥:產品平台分析 Shionogi & Co Ltd - Product Pipeline Review - 2016
出版日期: 2016年12月30日 內容資訊: 英文 88 Pages
簡介

鹽野義製藥是進行循環系統系、代謝系、感染疾病、免疫系、癌症性疼痛等領域的醫藥產品、診斷法、其他相關產品的製造銷售的製藥公司。該公司的為核心醫藥品產業,由處方箋藥、成藥、診斷藥構成。

本報告提供鹽野義製藥的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

鹽野義製藥的基本資料

  • 鹽野義製藥概要
  • 主要資訊
  • 企業資料

鹽野義製藥:R&D概要

  • 主要的治療範圍

鹽野義製藥:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

鹽野義製藥:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

鹽野義製藥:藥物簡介

鹽野義製藥:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

鹽野義製藥:最近的開發平台趨勢

鹽野義製藥:暫停中的計劃

鹽野義製藥:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • doripenem
    • lusutrombopag
    • S-234462
    • S-288310
    • S-444823
    • S-488410
    • S-5751
    • S-777469
    • S-8510
    • teceleukin
    • velneperit

鹽野義製藥:企業發表

鹽野義製藥:總公司和子公司的所在地

鹽野義製藥:主要製造設備

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08181CDB

Summary

Global Markets Direct's, 'Shionogi & Co Ltd - Product Pipeline Review - 2016', provides an overview of the Shionogi & Co Ltd's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Shionogi & Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Shionogi & Co Ltd
  • The report provides overview of Shionogi & Co Ltd including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Shionogi & Co Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Shionogi & Co Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Shionogi & Co Ltd's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Shionogi & Co Ltd
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Shionogi & Co Ltd's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Shionogi & Co Ltd Snapshot
    • Shionogi & Co Ltd Overview
    • Key Facts
  • Shionogi & Co Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Shionogi & Co Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Shionogi & Co Ltd - Pipeline Products Glance
    • Shionogi & Co Ltd - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Shionogi & Co Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Shionogi & Co Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Shionogi & Co Ltd - Drug Profiles
    • A-2NTX - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMG-0101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • asapiprant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cefiderocol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • doripenem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lusutrombopag - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit PcrV for Resistant Pseudomonas aeruginosa Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naldemedine tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ospemifene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oxycodone hydrochloride ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Agonize NPR1 and NPR2 for Non-Small Cell Lung Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rovatirelin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-010887 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-033188 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-117957 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-120083 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-222611 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-237648 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-488210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-588410 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-600918 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-707106 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize P2X3 Receptor for Neuropathic Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block TRPV4 for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Tuberculosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize CB2 for Pruritus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize NPY5R for Obesity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Penicillin Binding Protein for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SR-0379 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STAGR-120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Shionogi & Co Ltd - Pipeline Analysis
    • Shionogi & Co Ltd - Pipeline Products by Target
    • Shionogi & Co Ltd - Pipeline Products by Route of Administration
    • Shionogi & Co Ltd - Pipeline Products by Molecule Type
    • Shionogi & Co Ltd - Pipeline Products by Mechanism of Action
  • Shionogi & Co Ltd - Dormant Projects
  • Shionogi & Co Ltd - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ADX-415
      • capravirine
      • doripenem
      • GSK-364735
      • GW-810781
      • lisdexamfetamine dimesylate
      • lusutrombopag
      • S-234462
      • S-288310
      • S-444823
      • S-488410
      • S-5751
      • S-646240
      • S-777469
      • S-8510
      • teceleukin
      • varespladib sodium
      • velneperit
  • Shionogi & Co Ltd - Company Statement
  • Shionogi & Co Ltd - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Shionogi & Co Ltd, Key Facts
  • Shionogi & Co Ltd - Pipeline by Indication, 2016
  • Shionogi & Co Ltd - Pipeline by Stage of Development, 2016
  • Shionogi & Co Ltd - Monotherapy Products in Pipeline, 2016
  • Shionogi & Co Ltd - Combination Treatment Modalities in Pipeline, 2016
  • Shionogi & Co Ltd - Partnered Products in Pipeline, 2016
  • Shionogi & Co Ltd - Partnered Products/ Combination Treatment Modalities, 2016
  • Shionogi & Co Ltd - Out-Licensed Products in Pipeline, 2016
  • Shionogi & Co Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Shionogi & Co Ltd - Pre-Registration, 2016
  • Shionogi & Co Ltd - Phase III, 2016
  • Shionogi & Co Ltd - Phase II, 2016
  • Shionogi & Co Ltd - Phase I, 2016
  • Shionogi & Co Ltd - Preclinical, 2016
  • Shionogi & Co Ltd - Discovery, 2016
  • Shionogi & Co Ltd - Pipeline by Target, 2016
  • Shionogi & Co Ltd - Pipeline by Route of Administration, 2016
  • Shionogi & Co Ltd - Pipeline by Molecule Type, 2016
  • Shionogi & Co Ltd - Pipeline Products by Mechanism of Action, 2016
  • Shionogi & Co Ltd - Dormant Developmental Projects,2016
  • Shionogi & Co Ltd - Discontinued Pipeline Products, 2016
  • Shionogi & Co Ltd, Other Locations
  • Shionogi & Co Ltd, Subsidiaries

List of Figures

  • Shionogi & Co Ltd - Pipeline by Top 10 Indication, 2016
  • Shionogi & Co Ltd - Pipeline by Stage of Development, 2016
  • Shionogi & Co Ltd - Monotherapy Products in Pipeline, 2016
  • Shionogi & Co Ltd - Partnered Products in Pipeline, 2016
  • Shionogi & Co Ltd - Out-Licensed Products in Pipeline, 2016
  • Shionogi & Co Ltd - Pipeline by Top 10 Target, 2016
  • Shionogi & Co Ltd - Pipeline by Route of Administration, 2016
  • Shionogi & Co Ltd - Pipeline by Molecule Type, 2016
  • Shionogi & Co Ltd - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top